Originally Posted by mrsD
Yes, the Horizant form of extended release gabapentin, is more bioavailable at lower doses, so less is needed each day.
Since Lyrica is taken 3 times a day, normally, an extended release form, may also be more efficient leading to new dosing requirements.
I can't tell if there's still some confusion about this. From our previous discussion about the 2 new(er) forms of gabapentin:
AFAIK, it's the increased bioavailability that makes Horizant more efficient leading to new dosing requirements - not just the extended release factor.
(Admittedly pedantic, but technically correct.)
So I would think it stands to reason that more efficiency in dosing Lyrica/pregabalin may also require a more bioavailable form (I haven't seen the CafePharma thread, so I don't know if this was covered/mentioned). The patent clocks would likely be restarted in either event.
If this is all they've got in the way of next gen neuropathic pain medication (gabapentin--> pregabalin--> ???), I'm disappointed; it seems more like a stalling tactic. (Good Grief, I've succumbed to Internet-Age Immediate Gratification Impatience!